Investor Portal
Loading...
Home2019-10-22T11:03:31+01:00

Endeavour Vision is a leading private equity firm, focused exclusively on supporting growth-stage medtech companies.

Our team has unmatched sector and operational expertise, extensive international experience including product launches and accelerating company growth, in addition to a proven track record of successful exits.

Our mission is to transform the standard of care for millions of patients by investing in groundbreaking medical innovations.

Learn More
focused strategy

Focused Strategy

We invest exclusively in growth-stage medical technology companies – a specialised investment focus delivered by a specialist team.

icon dna

Entrepreneurial DNA

We started as entrepreneurs ourselves, so we know about building a business and how to manage the common pain points.

icon medtech

Experts in Medtech

Our team offers a wealth of experience in medical technology ranging from product launches and accelerated company growth to successful exits.

Latest Endeavour Vision News

View all

Allergan and Molecular Partners Present Late-Breaking Data from Phase 3 Studies of Investigational Abicipar pegol in Neovascular Wet Age-Related Macular Degeneration

Allergan and Molecular Partners Present Late-Breaking Data from Phase 3 Studies of Investigational Abicipar pegol [...]

Allergan & Molecular Partners Announce Acceptance of U.S. FDA Biologics License Application and Validation of EMA Marketing Authorisation

Allergan & Molecular Partners Announce Acceptance of U.S. FDA Biologics License Application and Validation [...]

Portfolio Companies

View all

Testimonials

View Companies

“As a trusted Board Member and Partner, Endeavour Vision brings a wealth of operational and financial experience to the team. They are interested in building companies the right way and creating a foundation for long-term accelerated growth, through a collaborative and detailed approach. Endeavour has always been a positive influence on our company and market. They are not only interested in representing transformational technologies but ensuring those technologies bring significant benefit to patients across the globe.”

Christopher M. OwensChristopher M. Owens, President & CEO, Gynesonics

“As the founding investor in CeQur, Endeavour Vision has been a great partner over the years, providing strategic input, on-going support and novel financing. The Endeavour Board Members bring a wealth of experience in R&D management, organizational management, marketing, regulatory affairs, clinical evaluation, and quality thus providing a resource for the CeQur management team to leverage as we work towards developing a successful product that will help thousands of patients with T2 diabetes achieve better glycemic control.”

Robert FarraRobert Farra, former CEO, CeQur Corporation
“We find in Endeavour Vision a unique and highly-sophisticated team, which adds significant value to our commercialization ramp-up. This includes strategic input, organizational development and talent acquisition. They’re an investment tteam which works closely with management to identify creative solutions to complex issues, leading the maximum value creation for the enterprise. I highly recommend Endeavour Vision as a valuable venture partner.”
Earl FenderEarl R.Fender, President & CEO, Vertiflex

“Chrono Therapeutics has been very pleased and impressed with Endeavour Vision medical product experience and domain knowledge. They have been engaged, supportive, thoughtful partners, particularly in the areas of regulatory strategy and product development.”

Alan LevyAlan Levy, former CEO, Chrono Therapeutics

“Endeavour Vision’s team brought an in-depth knowledge of our field – highlighted by impressive and thorough 360˚ due diligence, the long-term perspective required to build substantial companies, outstanding experience of bringing venture to financial success and an uncommon sense for team work. This is “smart money” at its best.”

Jaques R. Essinger, former CEO, Symetis

Sign up to receive our latest News

Sign Up